Revolution Medicines to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Revolution Medicines, a clinical-stage oncology company (Nasdaq: RVMD), announced participation in two investor conferences. CEO Mark A. Goldsmith will host fireside chats at the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on November 14, 2022, at 7:00 a.m. Eastern, and the 5th Annual Evercore ISI HealthCONx Conference from November 29 to December 1, 2022, with his chat scheduled for December 1 at 2:15 p.m. Eastern. Webcasts of the chats will be available online, with archived replays for at least 14 days.

REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured speaker in fireside chats at the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference and the 5^th Annual Evercore ISI HealthCONx Conference.

Details of these events are as follows:

• H.C. Wainwright 3^rd Annual Precision Oncology Virtual Conference
  Conference Date: November 14, 2022
  Fireside Chat Time/Date: 7:00 a.m. Eastern on Monday, November 14, 2022
  Format: Virtual conference; webcast available

• 5^th Annual Evercore ISI HealthCONx Conference
  Conference Date: November 29 – December 1, 2022
  Fireside Chat Time/Date: 2:15 p.m. Eastern on Thursday, December 1, 2022
  Format: Virtual conference; webcast available

Webcasts of the H.C. Wainwright and Evercore ISI fireside chats can be accessed at: https://ir.revmed.com/events-and-presentations. Archived replays of the webcasts will be available on the investors section of the company’s website for at least 14 days following the events.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RAS^MULTI) and RMC-6291(KRAS^G12C) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRAS^G12D), currently in IND-enabling development, RMC-8839 (KRAS^G13C), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

FAQ

What is the date of the H.C. Wainwright Virtual Conference for RVMD?

The H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference will be held on November 14, 2022.

When will Mark A. Goldsmith speak at the Evercore ISI HealthCONx Conference?

Mark A. Goldsmith will speak at the Evercore ISI HealthCONx Conference on December 1, 2022, at 2:15 p.m. Eastern.

How can I access the webcasts for Revolution Medicines' investor conferences?

Webcasts for the H.C. Wainwright and Evercore ISI conferences can be accessed at Revolution Medicines' investor website.

What therapies are being developed by Revolution Medicines?

Revolution Medicines is developing targeted therapies for RAS-addicted cancers, including RAS(ON) inhibitors and RAS companion inhibitors.